Figure 1 | Scientific Reports

Figure 1

From: Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

Figure 1

Study workflow. Overview of the in silico approach or our analysis methodology. Figure shows the main steps employed to simulate the MoA of emicizumab in the development of TMA in PwHA, including: (1) data compilation for molecular characterization of TMA and emicizumab, rFVIIa, and aPCC; (2) mathematical model generation using the validated top-down systems biology- and AI-based TPMS approach; and (3) data analyses employing model outputs. AI artificial intelligence, aPCC activated prothrombin complex concentrate, MoA mechanism of action, PwHA people with hemophilia A, rFVIIa recombinant activated factor VII, TMA thrombotic microangiopathy, TPMS Therapeutic Performance Mapping Systems.

Back to article page